Abstracts tagged "Arthritis, Infectious"

Abstract Number: 0963 • ACR Convergence 2020
Chronic Obstructive Pulmonary Disease Associated with Prolonged Opiate Use, Increased Short-Term Complications and the Need for Revision Surgery Following Total Knee Arthroplasty
Jillian Glasser¹, Nicholas Lemme², Daniel Yang², Edward Testa², Alan Daniels³ and Valentin Antoci³, ¹University Orthopedics Inc, East Providence, RI, ²Warren Alpert School of Medicine, Providence, RI, ³Warren Alpert School of Medicine, East Providence, RI
Background/Purpose: Chronic obstructive pulmonary disease (COPD) is a condition which causes a substantial burden to patients, physicians, and the healthcare system at large. Medical comorbidities…
Abstract Number: 0010 • ACR Convergence 2020
Antirheumatic Disease Therapies in Patients with COVID-19: A Systematic Review and Meta-analysis
Michael Putman¹, Yu Pei Eugenia Chock², Herman Tam³, Alfred Kim⁴, Sebastian Sattui⁵, Francis Berenbaum⁶, Maria (Maio) Danila⁷, Peter Korsten⁸, Catalina Sanchez Alvarez⁹, Jeffrey Sparks¹⁰, Laura Coates¹¹, Candace Palmerlee¹², Andrea Pierce¹³, Arundathi Jayatilleke¹⁴, Sindhu Johnson¹⁵, Adam Kilian¹⁶, Jean Liew¹⁷, Larry Prokop⁹, Hassan Murad⁹, Rebecca Grainger¹⁸, Zachary Wallace¹⁹ and Ali Duarte-Garcia⁹, ¹Northwestern University, Chicago, IL, ²Yale School of Medicine, Greenwich, CT, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Washington University School of Medicine, St. Louis, MO, ⁵Hospital for Special Surgery, New York, NY, ⁶Sorbonne Universit�, Paris, France, ⁷University of Alabama at Birmingham (UAB), Birmingham, AL, ⁸University Medical Center Göttingen, Gottingen, Germany, ⁹Mayo Clinic, Rochester, MN, ¹⁰Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Oxford, Oxford, United Kingdom, ¹²12. Patient Research Partner, Berkeley, CA, ¹³Patient Research Partner, New York City, ¹⁴Lewis Katz School of Medicine, Temple University, Philadelphia, PA, ¹⁵University of Toronto, Toronto, ON, Canada, ¹⁶George Washington University, Washington, DC, ¹⁷University of Washington, Seattle, WA, ¹⁸University of Otago, Wellington, New Zealand, ¹⁹Massachusetts General Hospital, Newton, MA
Background/Purpose: Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. There has been particular interest in the antimalarial agent…
Abstract Number: 0554 • ACR Convergence 2020
Increased Burden of Painful Arthritis and Rheumatism Following the Chikungunya Epidemic 2006: India Rural Population Survey 2018
Arvind Chopra¹, Ravi Ghorpade², Anuradha Venugopalan¹, Manjit Saluja¹ and Kiran Adam¹, ¹Center for Rheumatic Diseases, Pune, India, ²Center for Rheumatic Diseases, Pune
Background/Purpose: A spectrum of post Chikungunya (Chik) arthritis , often RA like, were referred to an urban rheumatology centre (Pune India)during the 2006 epidemic (Arthritis…
Abstract Number: 0625 • ACR Convergence 2020
Machine Learning Model to Predict Culture Positivity in Suspected Septic Arthritis
Vinit Gilvaz¹, Elinor Mody², Alwyn Rapose², Shree Radhakrishnan³, Saud Abaalkhail¹ and Sri Vibhavari Guntupalli¹, ¹Saint Vincent Hospital, Worcester, MA, ²Reliant medical group, Worcester, MA, ³Innovation Incubator Inc, San Jose, CA
Background/Purpose: Arthrocentesis is typically performed on patients with an acutely inflamed joint of unclear etiology. This is most often done to rule out septic arthritis,…
Abstract Number: 0738 • ACR Convergence 2020
Systemic Administration of Novel Hydroxyl Dendrimers to Target Inflammation in Arthritic Tissues
Jeffrey Cleland¹, Rishi Sharma², Minghao Sun³, Santiago Appiani La Rosa³ and Rangaramanujam M. Kannan⁴, ¹Ashvattha Therapeutics, Inc, Redwood City, CA, ²Ashvattha Therapeutics, Baltimore, MD, ³Ashvattha Therapeutics, Inc, Baltimore, MD, ⁴Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Chronic inflammation observed in arthritis and other autoimmune disorders is mediated primarily by pro-inflammatory reactive macrophages. Systemic administration of anti-inflammatory agents does not selectively…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].